Promethera's mission is to pioneer the development of cell therapies and complementary biopharmaceutical approaches to treat a broad variety of devastating and severe liver diseases with no effective therapeutic cure.
Promethera Biosciences’ mission is to apply its proprietary liver cell-based therapeutics and complimentary biological technologies to meet the needs of patients with acute and chronic liver diseases. The company is pioneering the development of cell-based therapies that provide both immunomodulatory and anti-fibrotic effects in the liver.
The company’s lead clinical program is derived from a patented allogenic liver cell platform called HepaStem. Currently in a Phase IIa clinical trial to treat patients with Acute-on-Chronic Liver Failure (ACLF), the program has the potential to target other severe and more prevalent chronic liver diseases such as Non-Alcoholic Steatohepatis (NASH).
Promethera has developed its cell therapy technologies by using allogenic stem and progenitor liver cells. These are isolated, purified and expanded from healthy human livers unsuitable for transplantation. The process for developing these cells into a medical treatment enables the delivery of the cells to patients directly at point of care.
Promethera has strengthened its development portfolio in 2018 through the acquisition of the Swiss biopharmaceutical company Baliopharm AG. As part of the transaction, Promethera added a complimentary therapeutic strategy to its portfolio of severe liver disease medicines by selectively targeting the TNF-alpha receptor 1 (TNF-R1) and is currently preclinically developing the novel antibody-based monovalent drug candidate Atrosimab towards clinical trials in NASH/Fibrosis indication.
PROMETHERA, Hepastem, H2stem, Cytonet, and Heparesc are registered trademarks or trademarks of PROMETHERA in the Benelux, the United States and other countries.